




Figure S1 Evaluation of survival outcomes in patients with clinical stage IA lung adenocarcinoma. (A) OS for without versus with staging brain MRI groups in patients with tumors <2 cm. (B) Overall RFS for without versus with staging brain MRI groups in patients with tumors <2 cm. (C) Brain metastases-specific RFS for without versus with staging brain MRI groups in patients with tumors <2 cm. (D) OS for without versus with staging brain MRI groups in patients with tumors ≥2 cm. (E) Overall RFS for without versus with staging brain MRI groups in patients with tumors ≥2 cm. (F) Brain metastases-specific RFS for without versus with staging brain MRI groups in patients with tumors ≥2 cm. MRI, magnetic resonance imaging; OS, overall survival; RFS, recurrence free survival.